Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079720" target="_blank" >RIV/00159816:_____/23:00079720 - isvavai.cz</a>

Result on the web

<a href="https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202305769" target="_blank" >https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202305769</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/advs.202305769" target="_blank" >10.1002/advs.202305769</a>

Result language

angličtina

Original language name

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles

Original language description

The application of lipid-based nanoparticles for COVID-19 vaccines and transthyretin-mediated amyloidosis treatment have highlighted their potential for translation to cancer therapy. However, their use in delivering drugs to solid tumors is limited by ineffective targeting, heterogeneous organ distribution, systemic inflammatory responses, and insufficient drug accumulation at the tumor. Instead, the use of lipid-based nanoparticles to remotely activate immune system responses is an emerging effective strategy. Despite this approach showing potential for treating hematological cancers, its application to treat solid tumors is hampered by the selection of eligible targets, tumor heterogeneity, and ineffective penetration of activated T cells within the tumor. Notwithstanding, the use of lipid-based nanoparticles for immunotherapy is projected to revolutionize cancer therapy, with the ultimate goal of rendering cancer a chronic disease. However, the translational success is likely to depend on the use of predictive tumor models in preclinical studies, simulating the complexity of the tumor microenvironment (e.g., the fibrotic extracellular matrix that impairs therapeutic outcomes) and stimulating tumor progression. This review compiles recent advances in the field of antitumor lipid-based nanoparticles and highlights emerging therapeutic approaches (e.g., mechanotherapy) to modulate tumor stiffness and improve T cell infiltration, and the use of organoids to better guide therapeutic outcomes. The implementation of advanced preclinical models such as tumor organoids, incorporating immune system cells and tumor extracellular matrix, will contribute to the development of innovative antitumor therapies such as mechanotherapy-assisted lipid-based immunotherapy.image

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NU23J-08-00035" target="_blank" >NU23J-08-00035: Integration of novel RNA-nanotherapeutics in patient-derived breast cancer organoids</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Advanced Science

ISSN

2198-3844

e-ISSN

2198-3844

Volume of the periodical

11

Issue of the periodical within the volume

8

Country of publishing house

US - UNITED STATES

Number of pages

21

Pages from-to

—

UT code for WoS article

001113841200001

EID of the result in the Scopus database

—